Bezisterim

Bezisterim
Clinical data
Other namesNE3107; NE-3107; HE3286; HE-3286; Triolex; 17α-Ethynyl-5-androstene-3β,7β,17β-triol; 17α-Ethynylandrost-5-ene-3β,7β,17β-triol
Routes of
administration		Oral
Drug classAnti-inflammatory agent; Insulin sensitizer
Legal status
Legal status
  • Investigational
Identifiers
  • (3S,7R,8R,9S,10R,13S,14S,17R)-17-ethynyl-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-3,7,17-triol
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H30O3
Molar mass330.468 g·mol−1
3D model (JSmol)
  • C[C@]12CC[C@@H](CC1=C[C@@H]([C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C#C)O)C)O)O
  • InChI=1S/C21H30O3/c1-4-21(24)10-7-16-18-15(6-9-20(16,21)3)19(2)8-5-14(22)11-13(19)12-17(18)23/h1,12,14-18,22-24H,5-11H2,2-3H3/t14-,15-,16-,17-,18+,19-,20-,21-/m0/s1
  • Key:JJKOQZHWYLMASZ-FJWDNACWSA-N

Bezisterim (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names NE3107, HE3286), also known as 17α-ethynylandrost-5-ene-3β,7β,17β-triol, is a synthetic analogue of dehydroepiandrosterone (DHEA) and its metabolite androstenetriol (AET) that is believed to have anti-inflammatory and insulin-sensitizing effects in the brain. The compound crosses the blood–brain barrier and does not activate any neurotransmitter receptors. It has been tested as a treatment for Alzheimer's disease, Parkinson's disease, traumatic brain injury, and post-acute COVID-19 syndrome (long COVID). The drug is under development for a variety of conditions and its highest developmental phase is phase 3 for Alzheimer's disease. Positive phase 2 findings for long COVID were released in October 2026.

See also

References

  1. 1 2 3 4 5 "Bezisterim". AdisInsight. 5 September 2024. Retrieved 26 September 2024.
  2. ↑ Reading, Chris L; Ahlem, Clarence N; Parameswaran, Narayanan (December 2021). "Rationale for an anti-inflammatory insulin sensitizer in a phase 3 Alzheimer's disease trial". Alzheimer's & Dementia. 17 (S9). doi:10.1002/alz.057438.
  3. ↑ Stoiljkovic, Milan; Horvath, Tamas L.; Hajós, Mihály (July 2021). "Therapy for Alzheimer's disease: Missing targets and functional markers?". Ageing Research Reviews. 68 101318. doi:10.1016/j.arr.2021.101318. PMC 8131215. PMID 33711510.
  4. ↑ Balzano, Tiziano; Esteban-García, Noelia; Blesa, Javier (2 January 2023). "Neuroinflammation, immune response and α-synuclein pathology: how animal models are helping us to connect dots". Expert Opinion on Drug Discovery. 18 (1): 13–23. doi:10.1080/17460441.2023.2160440. PMID 36538833. S2CID 254959175.
  5. ↑ Liu, Ping; Wang, Yunyun; Sun, Yan; Peng, Guoping (April 2022). "Neuroinflammation as a Potential Therapeutic Target in Alzheimer's Disease". Clinical Interventions in Aging. 17: 665–674. doi:10.2147/CIA.S357558. PMC 9064449. PMID 35520949.
  6. ↑ Xi, Yilong; Chen, Yun; Jin, Yi; Han, Guochen; Song, Mingjie; Song, Tingting; Shi, Yang; Tao, Ling; Huang, Zewei; Zhou, Jianping; Ding, Yang; Zhang, Huaqing (May 2022). "Versatile nanomaterials for Alzheimer's disease: Pathogenesis inspired disease-modifying therapy". Journal of Controlled Release. 345: 38–61. doi:10.1016/j.jconrel.2022.02.034. PMID 35257810. S2CID 247285338.
  7. ↑ "U.S. Clinical Trial: Neurological Associates of West Los Angeles Listed a New Clinical Trial to Study Insulin-sensitizing NE3107 in Improving Sleep and Fatigue in Subjects With Traumatic Brain Injury." Contify Life Science News, 1 Aug. 2023, p. NA. Gale OneFile: Health and Medicine, link.gale.com/apps/doc/A759542006/HRCA?u=anon~bb46c85&sid=sitemap&xid=0c315c7e. Accessed 14 Dec. 2023.
  8. ↑ Kuntz, Leah (19 October 2026). "New Phase 2 Data on Bezisterim for the Treatment of Long COVID". Psychiatric Times. MJH Life Sciences. Retrieved 20 October 2026.
  9. ↑ Markham, Penelope; Peluso, Michael; Reading, Christopher; Ahlem, Clarence; O'Quinn, Stephen; Samad, Navid A.; Zhang, Jeffrey; Palumbo, Joseph M. (12 October 2026). Results of a Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Bezisterim (NE3107) in Long COVID (ADDRESS-LC). 151st Annual Meeting of the American Neurological Association. Wiley. p. S187. doi:10.1002/ana.78378. ISSN 0364-5134.